Literature DB >> 9016326

Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]- 1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity.

A K Dutta1, L L Coffey, M E Reith.   

Abstract

Several analogs of the potent and selective dopamine transporter (DAT) ligand 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine, 1a, were prepared and biologically evaluated at the dopamine and serotonin transporter (SERT) sites. Several substituents were introduced in the aromatic rings to evaluate the influences of electronic and steric interactions in their binding to the DAT. All the novel analogs showed preferential interaction at the DAT compared with the SERT. Different aromatic substitutions in the phenyl ring of the N-benzyl part of the molecule played a key role in the selectivity. In general, compounds with strong electron-withdrawing substituents were most active and selective at the DAT. Thus, compounds 5a (R = F) and 11b (R = NO2) were among the most potent (IC50 = 17.2 and 16.4 nM, respectively) and most selective (SERT/DAT = 112 and 108, respectively) and were far more selective than GBR 12909 (SERT/DAT = 6). Bioisosteric replacement of one of the phenyl rings of the diphenylmethoxy moiety by a thiophene ring was tolerated well and produced the most potent compound 13b (IC50 = 13.8 nM) in the series. Our current structure-activity studies of these piperidine analogs resulted in the generation of second generation of GBR-type compounds, and all of these new compounds reported here were more selective than GBR 12909 in interacting with the DAT over the SERT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016326     DOI: 10.1021/jm960638e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Further structure-activity relationship studies on 8-substituted-3-[2-(diarylmethoxyethylidenyl)]-8-azabicyclo[3.2.1]octane derivatives at monoamine transporters.

Authors:  Shaine A Cararas; Sari Izenwasser; Dean Wade; Amy Housman; Abha Verma; Stacey A Lomenzo; Mark L Trudell
Journal:  Bioorg Med Chem       Date:  2011-10-18       Impact factor: 3.641

3.  Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection.

Authors:  J T Yorgason; S R Jones; R A España
Journal:  Neuroscience       Date:  2011-03-21       Impact factor: 3.590

4.  Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters.

Authors:  Prashant S Kharkar; Angela M Batman; Juan Zhen; Patrick M Beardsley; Maarten E A Reith; Aloke K Dutta
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

5.  Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters.

Authors:  Manoj Mishra; Rohit Kolhatkar; Juan Zhen; Ingrid Parrington; Maarten E A Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2008-01-11       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.